JP2021134211A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021134211A5 JP2021134211A5 JP2021023812A JP2021023812A JP2021134211A5 JP 2021134211 A5 JP2021134211 A5 JP 2021134211A5 JP 2021023812 A JP2021023812 A JP 2021023812A JP 2021023812 A JP2021023812 A JP 2021023812A JP 2021134211 A5 JP2021134211 A5 JP 2021134211A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- composition according
- tetrahydrospiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- UKBQFBRPXKGJPY-INIZCTEOSA-N 2-[5-(3-ethoxypyridin-2-yl)oxypyridin-3-yl]-N-[(3S)-oxolan-3-yl]pyrimidine-5-carboxamide Chemical compound C(C)OC=1C(=NC=CC=1)OC=1C=C(C=NC=1)C1=NC=C(C=N1)C(=O)N[C@@H]1COCC1 UKBQFBRPXKGJPY-INIZCTEOSA-N 0.000 claims 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 7
- 208000019425 cirrhosis of liver Diseases 0.000 claims 6
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 4
- 239000005711 Benzoic acid Substances 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 235000010233 benzoic acid Nutrition 0.000 claims 4
- 230000007882 cirrhosis Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- LXZMHBHEXAELHH-UHFFFAOYSA-N 4-[6-methoxy-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound N=1C(OC)=CC(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)=CC=1C1=CC=C(C(O)=O)C=C1 LXZMHBHEXAELHH-UHFFFAOYSA-N 0.000 claims 3
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000027032 Renal vascular disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000015670 renal artery disease Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980664P | 2020-02-24 | 2020-02-24 | |
| US62/980664 | 2020-02-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021134211A JP2021134211A (ja) | 2021-09-13 |
| JP2021134211A5 true JP2021134211A5 (enExample) | 2024-01-24 |
Family
ID=74844948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021023812A Pending JP2021134211A (ja) | 2020-02-24 | 2021-02-18 | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12472180B2 (enExample) |
| EP (1) | EP4110395A1 (enExample) |
| JP (1) | JP2021134211A (enExample) |
| AR (1) | AR121400A1 (enExample) |
| CA (1) | CA3172765A1 (enExample) |
| TW (1) | TW202140004A (enExample) |
| WO (1) | WO2021171164A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119219759B (zh) * | 2024-10-22 | 2026-03-27 | 浙江工业大学 | 一种双水相萃取耦合反相柱层析分离纯化发酵液中glp-1类似物的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| WO1992018106A1 (fr) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Procede de production d'une dispersion solide |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| ES2287971T3 (es) | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
| HRP20161178T1 (hr) * | 2010-09-30 | 2016-11-04 | Pfizer Inc. | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| EA201791258A1 (ru) | 2015-01-09 | 2017-12-29 | Джилид Аполло, Ллс | Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени |
| SI3397631T1 (sl) | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
| AR109179A1 (es) * | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| KR102314286B1 (ko) | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| CN111406056B (zh) | 2017-11-21 | 2023-02-28 | 辉瑞公司 | 选择性acc抑制剂的结晶2-氨基-2-(羟甲基)丙烷-1,3-二醇盐 |
| US11254660B2 (en) | 2018-08-31 | 2022-02-22 | Pfizer Inc. | Combinations for treatment of NASH/NAFLD and related diseases |
| WO2020234726A1 (en) * | 2019-05-20 | 2020-11-26 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
-
2021
- 2021-02-18 JP JP2021023812A patent/JP2021134211A/ja active Pending
- 2021-02-20 TW TW110105906A patent/TW202140004A/zh unknown
- 2021-02-22 WO PCT/IB2021/051479 patent/WO2021171164A1/en not_active Ceased
- 2021-02-22 CA CA3172765A patent/CA3172765A1/en active Pending
- 2021-02-22 EP EP21709111.5A patent/EP4110395A1/en active Pending
- 2021-02-22 US US17/904,537 patent/US12472180B2/en active Active
- 2021-02-23 AR ARP210100459A patent/AR121400A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4125896B1 (en) | Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| KR101699501B1 (ko) | 간기능부전 환자들에 대한 피르페니돈 치료법 | |
| JP2022121594A5 (enExample) | ||
| JP2023546125A5 (enExample) | ||
| CN111285829B (zh) | 一类PPARγ/δ双重激动剂、其制备方法及其作为药物的用途 | |
| CN103298466B (zh) | 茶碱和非布索坦的联合治疗方法 | |
| JP2019531320A5 (enExample) | ||
| JP2021134211A5 (enExample) | ||
| JP2019518738A (ja) | 組成物、ならびにその適用および薬学的調製の方法 | |
| KR20150046125A (ko) | Sglt2 저해약과 항고혈압약의 조합 | |
| JP2008512486A5 (enExample) | ||
| JP4804353B2 (ja) | 糖尿病の治療及び予防のためのフタリド誘導体の使用 | |
| IL305455A (en) | Aromatic compound, method of its preparation and use | |
| CN111202731A (zh) | 联合用药应用以及一种药用组合物及其应用 | |
| JP2004505042A (ja) | 糖尿病及びグルコース変性の予防及び／または治療のための方法及び組成物 | |
| JP2023543924A5 (enExample) | ||
| JP2019520381A (ja) | 光学活性ピラノクロメニルフェノール誘導体およびそれを含む薬学的組成物 | |
| CN106999458B (zh) | 用于预防和治疗糖尿病的经取代芳族化合物和药物组合物 | |
| JP7175383B2 (ja) | チアミン誘導体を含む血管又は弁膜石灰化の予防又は治療用の組成物 | |
| TW200409643A (en) | Preventive agents for diabetes mellitus | |
| CN107998385A (zh) | 水蛭素作为防治高尿酸血症药物的用途 | |
| CN101269040A (zh) | 盐酸吡格列酮缓释滴丸及其制备方法 | |
| CN103110626A (zh) | 一种药物组合物及其应用 | |
| WO2012115249A1 (ja) | スピロケタール誘導体の結晶 | |
| CN102532122B (zh) | 酒石酸罗格列酮的制备方法 |